Kerry Group plc (KRYAY) Q4 2025 Earnings Call Transcript

Q4 2025 Earnings Call February 17, 2026 3:00 AM ESTCompany ParticipantsWilliam Lynch - Head of Investor RelationsEdmond ...

CervoMed Inc.: CervoMed's neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis

Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational data in ALS-relevant neurotoxicity models UK ...

Halozyme Therapeutics, Inc.: Halozyme Reports Full Year 2025 Record Revenue Of $1.4 Billion And Reiterates Strong 2026 Financial Guidance

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billionFull Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions ...
The Lancet

Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of adults, with about 30% of cases progressing to metabolic dysfunction-associated steatohepatitis (MASH), ...